Objective: To describe a series of patients with heart failure supported with a ventricular assist device (VAD) who requested (or whose surrogates requested) withdrawal of VAD support and the legal and ethical aspects pertaining to these requests.
Patients And Methods: We retrospectively reviewed the medical records of patients at Mayo Clinic, Rochester, MN, from March 1, 2003, through January 31, 2009, who requested (or whose surrogates requested) withdrawal of VAD support and for whom the requests were fulfilled. We then explored the legal and ethical permissibility of carrying out such requests.
Results: The median age of the 14 patients identified (13 men, 1 woman) was 57 years. Requests were made by 2 patients and 12 surrogates. None of the patients' available advance directives mentioned the VAD. For 11 patients, multidisciplinary care conferences were held before withdrawal of VAD support. Only 1 patient had an ethics consultation. All 14 patients died within 1 day of withdrawal of VAD support.
Conclusion: Patients have the right to refuse or request the withdrawal of any unwanted treatment, and we argue that this right extends to VAD support. We also argue that the cause of death in these cases is the underlying heart disease, not assisted suicide or euthanasia. Therefore, patients with heart failure supported with VADs or their surrogates may request withdrawal of this treatment. In our view, carrying out such requests is permissible in accordance with the principles that apply to withdrawing other life-sustaining treatments.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2931614 | PMC |
| http://dx.doi.org/10.4065/mcp.2010.0113 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical impact of the use of chronic suppressive antibiotics against recurrent ventricular assist device infections.
Microbiol Spectr
November 2024
Department of Infectious Diseases, The University of Tokyo Hospital, Tokyo, Japan.
Unlabelled: Ventricular assist device (VAD) infections are frequent causes of hospital readmission. The risk factors and optimal preventive strategies for such, including chronic suppressive antibiotics (CSA), remain uncertain. We performed a single-center, retrospective, observational cohort study assessing continuous flow VAD recipients who underwent implantation between 2008 and 2018 in Japan.
View Article and Find Full Text PDFVenopulmonary Artery Extracorporeal Life Support (VPa ECMO): A Novel Strategy for Refractory Hypoxemia Complicating VV ECMO.
ASAIO J
May 2024
Research Center, Fundación Cardiovascular de Colombia, Piedecuesta, Santander, Colombia.
Refractory hypoxemia (RH) during venovenous extracorporeal membrane oxygenation (VV ECMO) support is a complex problem that limits the benefit of this therapy. The need for sustained deep sedation and delays in active rehabilitation are considered as a direct consequence of RH. Changing from VV ECMO to a configuration that returns the flow to pulmonary artery, such as venopulmonary extracorporeal membrane oxygenation (VPa ECMO) may decrease recirculation and improve systemic oxygen delivery.
View Article and Find Full Text PDFUse of Intracorporeal Durable LVAD Support in Children Using HVAD or HeartMate 3-A EUROMACS Analysis.
J Cardiovasc Dev Dis
August 2023
Department of Cardiac Surgery, University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium.
The withdrawal of HVAD in 2021 created a concern for the pediatric population. The alternative implantable centrifugal blood pump HeartMate 3 has since been used more frequently in children. This paper analyses the outcome of children on LVAD support provided with an HVAD or HM3.
View Article and Find Full Text PDFFirst-in-Man Use of a Modified Controller to Resolve HVAD Failure-to-Restart.
ASAIO J
September 2023
From the Division of Cardiology, University of Washington School of Medicine, Seattle, Washington.
Article Synopsis
- A case study is presented on a patient experiencing a Medtronic HeartWare ventricular assist device (HVAD) pump failure-to-restart, highlighting the risks still faced by patients since the device was withdrawn from the market in June 2021.
- Despite the device's market withdrawal, around 4,000 patients globally continue to rely on HVAD support, putting them at risk for serious complications.
- The report introduces a new HVAD controller that successfully restarted a malfunctioning pump, demonstrating its potential to prevent life-threatening situations and reduce the need for device replacement.
Results of non-elective withdrawal of continuous-flow left ventricular assist devices in selected patients.
J Heart Lung Transplant
May 2023
Department of Cardiothoracic and Vascular Surgery, German Heart Center Berlin, Berlin, Germany.
Background: Protocols have been developed to identify patients for elective withdrawal of continuous-flow left ventricular device (cfLVAD) support. However, little is known about non-elective explantation or decommissioning of cfLVADs.
Methods: A retrospective analysis of all patients who underwent left ventricular assist device (LVAD) explantation or decommissioning at a single center between 2002 and 2021 was performed.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!